Micro-Comparison
    PCOS

    Semaglutide vs Tirzepatide for PCOS

    PCOS affects 1 in 10 women and is closely linked to insulin resistance. Here is how the two leading GLP-1 medications compare for managing PCOS symptoms.

    Published: April 3, 2026-9 min read

    Medical Disclaimer: PCOS management requires comprehensive care. GLP-1 medications are not FDA-approved specifically for PCOS. Consult your gynecologist or endocrinologist.

    Polycystic ovary syndrome is fundamentally a metabolic disorder driven by insulin resistance. That makes GLP-1 medications a compelling treatment option. Both semaglutide and tirzepatide address the root cause of PCOS, but their approaches differ.

    Why GLP-1 Works for PCOS

    • Insulin resistance: The core driver of PCOS in most women. Both medications improve insulin sensitivity
    • Weight loss: Even modest weight loss (5-10%) can restore ovulation, reduce androgens, and improve symptoms
    • Androgen reduction: Improved insulin sensitivity reduces ovarian androgen production, improving acne and hirsutism
    • Inflammation: GLP-1 medications reduce systemic inflammation, which contributes to PCOS pathology

    Head-to-Head for PCOS

    PCOS FactorSemaglutideTirzepatide
    Insulin resistance improvementGoodSuperior
    Weight loss (key for PCOS)~15%~21%
    A1C improvementGoodSuperior
    Reproductive safety dataMore published dataLess published data
    Must stop before conceptionYes (2+ months)Yes (2+ months)

    PCOS, Fertility, and GLP-1

    For women with PCOS trying to conceive, GLP-1 medications can be transformative but require careful timing:

    • Use GLP-1 medication to achieve weight loss and improve insulin resistance
    • Stop medication at least 2 months before attempting conception
    • The metabolic improvements from weight loss persist after stopping medication
    • Many women with PCOS spontaneously ovulate after achieving 5-10% weight loss
    • If pursuing IVF, see our GLP-1 before IVF guide

    The Bottom Line

    Our Assessment

    Tirzepatide may have a slight advantage for PCOS due to superior insulin resistance improvement and greater weight loss. However, semaglutide is also highly effective and has more published reproductive safety data. Both are excellent tools for managing PCOS when combined with lifestyle modifications. Work closely with your gynecologist or endocrinologist.

    Frequently Asked Questions

    Which GLP-1 is better for PCOS?

    Tirzepatide may have an edge for PCOS due to superior improvements in insulin resistance, which is the core metabolic driver of PCOS. However, both medications can produce the 5-10% weight loss that significantly improves PCOS symptoms. The best choice depends on your full health profile.

    Can GLP-1 restore ovulation in PCOS?

    Yes. Weight loss of 5-10% can restore regular ovulation in many women with PCOS. Both semaglutide and tirzepatide can achieve this level of weight loss. However, GLP-1 medications should be stopped before attempting conception.

    Will GLP-1 help with PCOS acne and hair growth?

    By improving insulin resistance and reducing androgen levels through weight loss, GLP-1 medications can improve PCOS-related acne and hirsutism over time. These changes typically take 3-6 months to become noticeable as hormone levels normalize.

    Can I take GLP-1 with metformin for PCOS?

    Yes. Many PCOS patients take GLP-1 medications alongside metformin. The two drugs work through different mechanisms and can be complementary. However, combining them may increase GI side effects. Your provider will determine the right combination for you.

    Address the Root Cause of PCOS

    Trimi offers affordable GLP-1 treatment to help manage PCOS through weight loss and metabolic improvement.

    Get Started Today

    Sources & References

    1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
    2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
    3. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
    4. FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).

    Medically Reviewed

    TMRT

    Trimi Medical Review Team

    Clinical review workflow for GLP-1 safety, dosing, and access content

    Team-based medical review process documented in Trimi's Medical Review Policy

    Last reviewed: April 7, 2026

    TCCT

    Written by Trimi Clinical Content Team

    Medical Writers & Healthcare Professionals

    Our clinical content team includes registered nurses, pharmacists, and medical writers who specialize in translating complex medical information into clear, actionable guidance for patients.

    Editorial Standards

    Trimi publishes patient education using a medical-review workflow, source-based claim checks, and dated updates for fast-changing pricing, access, and safety topics.

    Review our Editorial Policy and Medical Review Policy for more details about sourcing, updates, and reviewer attribution.

    Was this article helpful?

    Keep Reading

    Complete cost breakdown of semaglutide, tirzepatide, and retatrutide. Brand-name vs. compounded pricing, insurance coverage, and cost-per-pound-lost analysis.

    Read our guide on Compounding Vs Manufacturing.

    Complete side effect comparison of semaglutide, tirzepatide, and retatrutide. Nausea, GI issues, hair loss, fatigue, and unique side effects of each medication.

    A structured decision framework to choose between semaglutide, tirzepatide, and retatrutide based on your health profile, goals, budget, and risk tolerance.